Role for PET (Positron emission tomography) as breast cancer theranostic:
This article was originally published in Clinica
Positron emission tomography (PET) could prove useful in theranostic tests for breast cancer. So say Australian scientists based at the Monash Medical Centre in Melbourne, who have found that the technology can monitor women's response to chemotherapy, more effectively than mammography and ultrasound. According to the data, women who have a larger percentage drop in FDG-PET readings of their tumours, after receiving chemotherapy, were more likely to have a complete response to the treatment, and hence survive. FDG-PET could prove an important addition to conventional imaging of breast cancer, and may contribute significantly to more personalised disease management, claimed the researchers. They presented their results at the conference of the European CanCer Organisation (ECCO) in Barcelona, Spain, from 23-27 September.